To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
7 Current news about the topic velcaderss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Velcade (bortezomib).On 2 September 2011, Janssen-Cilag International NV ...
BioInvent International AB announced that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density. The results were presented at the American Society of Hematology (ASH) Annual Meeting.The ...
Aeterna Zentaris Inc. announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer. The ...
TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous belinostat (PXD101), a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade® ...
Phase I trial to establish the dose and frequency for oral PXD101 in patients with advanced solid tumors
CuraGen Corporation and TopoTarget A/S announced the initiation of a Phase I clinical trial evaluating the administration of oral PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. The Phase I trial will be led by Dr. W. Kevin Kelly, Associate ...
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with azacitidine for the treatment of advanced hematologic ...
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade(R) (bortezomib) for the treatment of relapsed, refractory multiple ...